98%
921
2 minutes
20
Background: The aim of this study was to compare the safety and efficacy of biodegradable-polymer (BP) drug-eluting stents (DES), bare metal stents (BMS), and durable-polymer DES in patients undergoing coronary revascularization, we performed a systematic review and network meta-analysis using a Bayesian framework.
Methods And Results: Study stents included BMS, paclitaxel-eluting (PES), sirolimus-eluting (SES), endeavor zotarolimus-eluting (ZES-E), cobalt-chromium everolimus-eluting (CoCr-EES), platinium-chromium everolimus-eluting (PtCr-EES), resolute zotarolimus-eluting (ZES-R), and BP biolimus-eluting stents (BP-BES). After a systematic electronic search, 113 trials with 90 584 patients were selected. The principal endpoint was definite or probable stent thrombosis (ST) defined according to the Academic Research Consortium within 1 year.
Results: Biodegradable polymer-biolimus-eluting stents [OR, 0.56; 95% credible interval (CrI), 0.33-0.90], SES (OR, 0.53; 95% CrI, 0.38-0.73), CoCr-EES (OR, 0.34; 95% CrI, 0.23-0.52), and PtCr-EES (OR, 0.31; 95% CrI, 0.10-0.90) were all superior to BMS in terms of definite or probable ST within 1 year. Cobalt-chromium everolimus-eluting stents demonstrated the lowest risk of ST of all stents at all times after stent implantation. Biodegradable polymer-biolimus-eluting stents was associated with a higher risk of definite or probable ST than CoCr-EES (OR, 1.72; 95% CrI, 1.04-2.98). All DES reduced the need for repeat revascularization, and all but PES reduced the risk of myocardial infarction compared with BMS.
Conclusions: All DESs but PES and ZES-E were superior to BMS in terms of ST within 1 year. Cobalt-chromium everolimus-eluting stents was safer than any DES even including BP-BES. Our results suggest that not only the biodegradability of polymer, but the optimal combination of stent alloy, design, strut thickness, polymer, and drug all combined determine the safety of DES.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/eurheartj/eht570 | DOI Listing |
Joint Bone Spine
September 2025
Université de Lorraine, Inserm, UMR INSPIIRE, Nancy, France; CHRU de Nancy, Inserm, Université de Lorraine, CIC Epidémiologie clinique, Nancy, France.
Objective: To describe whether rheumatoid arthritis (RA) flares detected by the self-administered Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire can predict joint structural damage progression at 2 years and to explore the association between the FLARE-RA score and RA outcome measures.
Methods: Adults with RA for less than 10 years and Health Assessment Questionnaire-Disability Index (HAQ-DI) score <1 were included in this prospective observational study. Patients were followed clinically every 6 months and completed the FLARE-RA questionnaire every 3 months at home, for 24 months.
Int J Epidemiol
August 2025
School of Population Health, Faculty of Health Sciences, Curtin University, Bentley, Western Australia, Australia.
Background: Country-level estimates can mask local geographic variations in progress toward achieving World Health Organization's End TB targets. This study aimed to identify spatial variations in progress toward achieving the TB incidence reduction target at a district level in Ethiopia.
Methods: A Bayesian linear regression model with a conditional autoregressive prior structure was developed to identify drivers of spatial variations in TB incidence reduction across districts and to identify spatial patterns and variations in TB incidence reduction across Ethiopia from 2015 to 2020.
Maturitas
August 2025
The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510030, China. Electronic address:
Background: Nonpharmacological therapies are widely used to improve the sleep quality of menopausal women experiencing insomnia. It is necessary to clarify which of the nonpharmacological therapies studied in randomized controlled trials are most effective and comprehensively evaluate their impacts.
Method: We conducted a systematic search across PubMed, Embase, the Cochrane Central Register of Controlled Trials, and the Web of Science from their inception until May 25, 2025.
Lancet
September 2025
Department of Cardiology, First Hospital of China Medical University, Shenyang, China. Electronic address:
Background: Although intensive blood pressure control is recommended by major guidelines, its overall benefit-harm balance remains uncertain. In particular, it is unclear how net clinical benefit varies by blood pressure target and patient characteristics. We aimed to quantify the benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control.
View Article and Find Full Text PDFPLoS Negl Trop Dis
September 2025
Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States of America.
Background: Canine Chagas disease is a vector-borne parasitic disease caused by Trypanosoma cruzi. T. cruzi is transmitted by triatomine bugs (a.
View Article and Find Full Text PDF